A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2002
12/19/2002	WO2002085308A3 Antisense and anti-inflammatory based compositions to treat respiratory disorders
12/19/2002	WO2002080981A3 Polynucleotide binding complexes comprising sterols and saponins
12/19/2002	WO2002076396A3 Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
12/19/2002	WO2002074243A3 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
12/19/2002	WO2002070561A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070560A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070558A3 Nuclear hormone receptor ligand binding domain
12/19/2002	WO2002070515A3 Chromane derivatives, process for their preparation and their use as antitumor agents
12/19/2002	WO2002066624A3 Novel human protease and polynucleotides encoding the same
12/19/2002	WO2002066012A3 Amphoteric liposomes and the use thereof
12/19/2002	WO2002060894A3 Sulfonamide lactam inhibitors of factor xa
12/19/2002	WO2002059080A3 Trisubstituted carbocyclic cyclophilin binding compounds and their use
12/19/2002	WO2002058626A9 Methods and compositions for the identification and treatment of neurodegenerative disorders
12/19/2002	WO2002057222A3 Thiol-based naaladase inhibitors
12/19/2002	WO2002055542A3 Hpv-specific peptides, which block the binding of hpv to the host cell
12/19/2002	WO2002055501A3 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
12/19/2002	WO2002044360A3 Modified arginine deiminase
12/19/2002	WO2002028887A3 Use of lipopeptides or lipoproteins for treating lung infections and lung tumours
12/19/2002	WO2002013847A3 Methods for diagnosis and therapy of hematological and virus-associated malignancies
12/19/2002	WO2002008287A3 Nk cells activating receptors and their therapeutic and diagnostic uses
12/19/2002	WO2001077169A9 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
12/19/2002	WO2001072994A9 Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof
12/19/2002	WO2001072977A9 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
12/19/2002	WO2001068859A9 Il-17 receptor like molecules and uses thereof
12/19/2002	WO2001068679A9 Peptides targeting specifically tumor-derived endothelial cells
12/19/2002	WO2001047919A9 Substituted oxazolidinones and their use in the field of blood coagulation
12/19/2002	US20020193612 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
12/19/2002	US20020193571 Wsx receptor agonist antibodies
12/19/2002	US20020193561 P53 protein variants and therapeutic uses thereof
12/19/2002	US20020193434 Stilbene derivative and a platinum coordination compound
12/19/2002	US20020193432 Useful as modulators of the interaction between the receptor for advanced glycated end product and its ligands
12/19/2002	US20020193431 Administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4, Lipoxin-A4, 15-epi-lipoxin4 or 15-R/S-methyl-lipoxin4 or salts, esters, amides, carboxylic acids or prodrugs to treat angiogenesis
12/19/2002	US20020193425 Cancer chemopreventative compounds and compositions and methods of treating cancers
12/19/2002	US20020193419 Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents
12/19/2002	US20020193416 Synergistic tumorcidal response induced by histamine
12/19/2002	US20020193410 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans
12/19/2002	US20020193409 Prodrugs of anticancer agents employing substituted aromatic acids
12/19/2002	US20020193405 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases
12/19/2002	US20020193396 Sulfonamido ether substituted imidazoquinolines
12/19/2002	US20020193384 Using azoles for the preparation of topical formulation for the prevention of radiation-induced skin cancer
12/19/2002	US20020193377 Quinazolines as MMP-13 inhibitors
12/19/2002	US20020193371 Using compound which inhibits expression of the gene TPT1 (translationally controlled tumor protein encoding histamine releasing factor) or of the products which it controls, for producing a drug which is intended for treating cancer
12/19/2002	US20020193362 Anti-tumor composition
12/19/2002	US20020193339 Antiviral agent for use in treatment of cancer
12/19/2002	US20020193329 Useful as vaccines
12/19/2002	US20020193318 Administering compound that binds human serum albumin (HSA) to increase free drug levels of the camptothecin compound during anti-topoisomerase I-based therapy in human
12/19/2002	US20020193316 Caloporoside derivatives, methods of their preparation and use
12/19/2002	US20020193311 Novel cytostatic conjugates with integrin ligands
12/19/2002	US20020193309 Contacting the sample or tissue with fibroblast growth factor 9 (FGF9) and allowing formation of receptor-ligand pairs; detecting presence of FGFR3-FGF9 pairs, a positive detection indicating presence of FGFR3 in the sample or tissue
12/19/2002	US20020193308 Recombinant protein and its use in therapy and diagnostics
12/19/2002	US20020193302 Use of FVIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
12/19/2002	US20020193283 Inhibitors of prenyl-protein transferase
12/19/2002	US20020192826 Recombinant AAV vector-based transduction system and use of same
12/19/2002	US20020192800 Nucleotide sequences coding polypeptide for use in the prevention, diagnosis and treatment of thrombosis, emphysema and liver disorders
12/19/2002	US20020192787 Polypeptide for use in the diagnosis, treatment, and prevention of cancer and developmental defects
12/19/2002	US20020192785 For use in therapeutics, diagnostics, and as research tools
12/19/2002	US20020192749 Human polynucleotides, polypeptides, and antibodies
12/19/2002	US20020192737 Detecting modulators of oxidoreductases; obtain sample, incubate with modulator, detect signal, monitor adjustment in enzyme activity
12/19/2002	US20020192729 Apoptosis protein for use in the diagnosis and treatment of cell proliferative disorders
12/19/2002	US20020192695 Detection of modulator of tumor suppressor activity; obtain sample of polypeptide, incubate with modulator, monitor adjustment in polypeptide activity
12/19/2002	US20020192682 Polynucleotides and polypeptides of the IFNalpha-2 gene
12/19/2002	US20020192681 Detection of parasite in sample; obtain sample, isolate nucleotide sequences from dendritic cells, determine gene expression, presence of preferential gene indicates infections
12/19/2002	US20020192647 Diagnostic method
12/19/2002	US20020192644 Detection of natural killer receptor; obtain samples, incubate with oligonucleotides, detect bound complexes, presence of complexes indicates receptor
12/19/2002	US20020192643 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferation or inflammatory disorders
12/19/2002	US20020192638 Evaluation of cells sensitvity to anticancer agents; obtain tissue, separate, culture tissue, inoculate cells, incubate with anticancer agent, monitor sensitivity to anticancer agents
12/19/2002	US20020192305 Inflammatory mediation obtained from atractylodes lancea
12/19/2002	US20020192228 Protein markers for lung cancer and use thereof
12/19/2002	US20020192227 Vaccines against cancer and infectious diseases
12/19/2002	US20020192220 Compositions and methods relating to colon specific genes and proteins
12/19/2002	US20020192216 Therapeutic use
12/19/2002	US20020192199 Composition and methods for enhanced tumor cell immunity in vivo
12/19/2002	US20020192195 Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
12/19/2002	US20020192184 Use of stabilized oligonucleotides for preparing a medicament with antitumor activity
12/19/2002	CA2487039A1 Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
12/19/2002	CA2487038A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
12/19/2002	CA2450663A1 Brca1/acc alpha molecular complexes, diagnostic and therapeutic applications
12/19/2002	CA2450379A1 Molecular signatures of commonly fatal carcinomas
12/19/2002	CA2450316A1 Cd10-activated prodrug compounds
12/19/2002	CA2450285A1 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
12/19/2002	CA2450027A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449934A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449649A1 A g-protein coupled receptor and uses therefor
12/19/2002	CA2449629A1 Pyrrolidine derivatives as factor xa inhibitors
12/19/2002	CA2449544A1 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
12/19/2002	CA2449517A1 Tissue-specific endothelial membrane proteins
12/19/2002	CA2449440A1 Structural and cytoskeleton-associated proteins
12/19/2002	CA2449272A1 Intracellular signaling molecules
12/19/2002	CA2447687A1 Substituted 1-benzazepines and derivatives thereof
12/19/2002	CA2447557A1 Using supercritical fluids to infuse therapeutic on a medical device
12/19/2002	CA2446223A1 Stabilized dispersion of phytosterol in oil
12/19/2002	CA2445471A1 Quinuclidine-substituted heteroaromatic compounds as ligands at nicotic acetylcholine receptors
12/19/2002	CA2445467A1 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
12/18/2002	EP1267171A1 Cofactor-based screening method for nuclear receptor modulators
12/18/2002	EP1266899A2 Rapamycin hdroxyesters, process for their preparation and pharmaceutical compositions containing them
12/18/2002	EP1266887A2 Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them
12/18/2002	EP1266661A1 Anticancer compositions
12/18/2002	EP1266658A2 Use of betulinic acid derivatives for the treatment and prevention of melanoma
12/18/2002	EP1266026A1 Modulation of pleiotrophin signaling by receptor-type protein tyrosine phosphatase beta/zeta
12/18/2002	EP1266023A2 LIPOPOLYSACCHARIDES (LPS) EXTRACTED FROM i ESCHERICHIA COLI /i

1 ... 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 ... 2211